Health Minister Mansukh Mandaviya, Science and Technology Minister Jitendra Singh launched Bharat Biotech’s Nasal Covid Vaccine Incovac (iNCOVACC). This is the world’s first Kovid-19 intranasal vaccine. The vaccine developed by Bharat Biotech will be available to the government at Rs 325 per dose, while it will cost Rs 800 to private hospitals.
Explain that Bharat Biotech was approved in December 2022 as the primary 2-dose and heterologous booster. iNCOVACC has been developed in partnership with Washington University, St. Louis. Bharat Biotech said that two doses of the vaccine have to be given at an interval of 28 days. An appointment can be booked by visiting the Covin website to get the dose.
The vaccine launch program was organized at Mandaviya’s residence on the occasion of Republic Day. In December, Bharat Biotech announced that it would sell the intranasal vaccine at Rs 325 per shot for government procurement and Rs 800 per shot for private vaccination centres. Bharat Biotech’s nasal vaccine, BBV154, got the approval of the Drugs Controller General of India in November.
iNCOVACC (BBV154) is a recombinant replication deficient adenovirus vectored vaccine with pre-fusion stabilized spike protein. The Hyderabad-based vaccine maker had said that the vaccine was evaluated in Phase I, II and III clinical trials with successful results.